Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8919191 | 0.86 | CA2 (0.44) | CA2CA4CA1CA6IMPDH2 | |
| SCHEMBL3044602 | 0.79 | IMPDH2 (0.31) | CA2CA4CA1CA6IMPDH2 | |
| SCHEMBL2029504 | 0.79 | IMPDH2 (0.33) | CA2CA4CA1CA6IMPDH2 | |
| SCHEMBL7508538 | 0.79 | CA2 (0.34) | CA2CA4CA1CA6IMPDH2 | |
| SCHEMBL9549629 | 0.79 | CA2 (0.46) | CA2CA4IMPDH2IMPDH1 | |
| SCHEMBL9310576 | 0.79 | CNR2 (0.49) | CNR2GPR55 | |
| SCHEMBL2952712 | 0.78 | ACHE (0.40) | CA2CA4CA1CA6 | |
| SCHEMBL9309164 | 0.77 | LTA4H (0.50) | CA2CA1 | |
| SCHEMBL1783169 | 0.75 | HTR2A (0.46) | IMPDH2IMPDH1 | |
| SCHEMBL1820953 | 0.75 | IMPDH2 (0.32) | IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770515-B2 | Crosslinking of proteins and other entities via conjugates of α-haloacetophenones, benzyl halides, quinones, and their derivatives | ADVANCED PROTEOME THERAPEUTICS INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20130165382-A1 | CROSSLINKING OF PROTEINS AND OTHER ENTITIES VIA CONJUGATES OF ALPHA-HALOACETOPHENONES, BENZYL HALIDES, QUINONES, AND THEIR DERIVATIVES | ADVANCED PROTEOME THERAPEUTICS INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165382-A1 | CROSSLINKING OF PROTEINS AND OTHER ENTITIES VIA CONJUGATES OF ALPHA-HALOACETOPHENONES, BENZYL HALIDES, QUINONES, AND THEIR DERIVATIVES | TBCA, HSP90AB2P, HSP90B1 | CA2 2962/4885CA4 2988/4885CA1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.